Related Experiment Video

Updated: Jun 18, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment?

Heli Lahtela1, Pasi P Karjalainen, Matti Niemelä

  • 1Department of Medicine, Turku University Hospital, Turku, Finland.

Thrombosis and Haemostasis
|December 8, 2009
PubMed

Insights

Glycoprotein IIb/IIIa inhibitors (GPIs) significantly increase major bleeding risk in atrial fibrillation patients undergoing percutaneous coronary intervention (PCI) on warfarin. Caution is advised when using GPIs in this high-risk population.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) patients often require anticoagulation with warfarin.
  • Percutaneous coronary intervention (PCI) is a common procedure for coronary artery disease.
  • The safety of glycoprotein IIb/IIIa inhibitors (GPIs) in AF patients on warfarin undergoing PCI is not well-established.

Purpose of the Study:

  • To evaluate the safety of using GPIs during PCI in patients with AF on chronic warfarin therapy.
  • To identify risk factors for major bleeding in this patient cohort.

Main Methods:

  • Retrospective analysis of 377 AF patients on warfarin undergoing PCI across seven centers.
  • Data collection included periprocedural GPI use, bleeding events, access site complications, and major adverse cardiovascular events.
  • Multivariable analysis and propensity score adjustment were used to assess the impact of GPIs on bleeding risk.

Main Results:

  • 29% of patients received periprocedural GPIs, with significant inter-hospital variation.
  • GPI use was higher in patients with ST-elevation myocardial infarction.
  • Major bleeding occurred more frequently in patients treated with GPIs (9.0% vs. 1.5%, p=0.001).
  • GPI use (OR 5.1) and older age (OR 1.2) were independent predictors of major bleeding.
  • GPIs remained a significant predictor of major bleeding even after propensity score adjustment (OR 3.8).
  • Periprocedural INR levels and warfarin pause did not predict major bleeding in the GPI group.

Conclusions:

  • GPIs significantly increase the risk of major bleeding in AF patients on warfarin undergoing PCI.
  • The increased bleeding risk associated with GPIs is independent of periprocedural INR levels.
  • GPIs should be used with caution in this fragile patient population due to elevated bleeding risk.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...